Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

References

1. Ayoub W.S., Keeffe E.B. 2011; Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 34:1145–1158 [View Article][PubMed]
   [Google Scholar]
2. Bloom K., Ely A., Mussolino C., Cathomen T., Arbuthnot P. 2013; Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 21:1889–1897 [View Article][PubMed]
   [Google Scholar]
3. Cao L., Wu C., Shi H., Gong Z., Zhang E., Wang H., Zhao K., Liu S., Li S., other authors. 2014; Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses. J Virol 88:8656–8666 [View Article][PubMed]
   [Google Scholar]
4. Chan H.L. 2011; Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. J Gastroenterol Hepatol 26:8–12 [View Article][PubMed]
   [Google Scholar]
5. Chudy M., Hanschmann K.M., Kress J., Nick S., Campos R., Wend U., Gerlich W., Nübling C.M. 2012; First WHO International Reference Panel containing hepatitis B virus genotypes A–G for assays of the viral DNA. J Clin Virol 55:303–309 [View Article][PubMed]
   [Google Scholar]
6. Cradick T.J., Fine E.J., Antico C.J., Bao G. 2013; CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41:9584–9592 [View Article][PubMed]
   [Google Scholar]
7. Ebina H., Misawa N., Kanemura Y., Koyanagi Y. 2013; Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3:2510 [View Article][PubMed]
   [Google Scholar]
8. Gaj T., Gersbach C.A., Barbas C.F. III 2013; ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397–405 [View Article][PubMed]
   [Google Scholar]
9. Hao R., He J., Liu X., Gao G., Liu D., Cui L., Yu G., Yu W., Chen Y., other authors. 2015; Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6. J Virol 89:4345–4355 [CrossRef]
   [Google Scholar]
10. Hsu P.D., Scott D.A., Weinstein J.A., Ran F.A., Konermann S., Agarwala V., Li Y., Fine E.J., Wu X., other authors. 2013; DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31:827–832 [View Article][PubMed]
    [Google Scholar]
11. Hsu P.D., Lander E.S., Zhang F. 2014; Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262–1278 [View Article][PubMed]
    [Google Scholar]
12. Huang L.R., Wu H.L., Chen P.J., Chen D.S. 2006; An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A 103:17862–17867 [View Article][PubMed]
    [Google Scholar]
13. Jablonowski H. 2003; IFN-alpha: therapeutic options in HIV and HIV/HCV, HIV/HBV dual infection. Infection 31:131–133[PubMed]
    [Google Scholar]
14. Januszkiewicz-Lewandowska D., Rucka A., Kowala-Piaskowska A., Bereszynska I., Mozer-Lisewska I., Zajac-Spychala O., Wysocki J., Nowak J. 2014; Mutations in Pol gene of hepatitis B virus in patients with chronic hepatitis B before and after therapy with nucleoside/nucleotide analogues. Acta Virol 58:185–189 [View Article][PubMed]
    [Google Scholar]
15. Joung J.K., Sander J.D. 2013; TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14:49–55 [View Article][PubMed]
    [Google Scholar]
16. Kennedy E.M., Bassit L.C., Mueller H., Kornepati A.V., Bogerd H.P., Nie T., Chatterjee P., Javanbakht H., Schinazi R.F., Cullen B.R. 2014; Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476:196–205 [View Article][PubMed]
    [Google Scholar]
17. Li F., Zhang D., Li Y., Jiang D., Luo S., Du N., Chen W., Deng L., Zeng C. 2015; Whole genome characterization of hepatitis B virus quasispecies with massively parallel pyrosequencing. Clin Microbiol 21:280–287 [CrossRef]
    [Google Scholar]
18. Lin S.R., Yang H.C., Kuo Y.T., Liu C.J., Yang T.Y., Sung K.C., Lin Y.Y., Wang H.Y., Wang C.C., other authors. 2014; The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo . Mol Ther Nucleic Acids 3:e186 [View Article][PubMed]
    [Google Scholar]
19. Liu D., Wu A., Cui L., Hao R., Wang Y., He J., Guo D. 2014a; Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β. PLoS One 9:e91658 [View Article][PubMed]
    [Google Scholar]
20. Liu J., Kosinska A., Lu M., Roggendorf M. 2014b; New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin 29:10–16 [View Article][PubMed]
    [Google Scholar]
21. Mani M., Kandavelou K., Dy F.J., Durai S., Chandrasegaran S. 2005; Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun 335:447–457 [View Article][PubMed]
    [Google Scholar]
22. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. 2006; The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538 [View Article][PubMed]
    [Google Scholar]
23. Schädler S., Hildt E. 2009; HBV life cycle: entry and morphogenesis. Viruses 1:185–209 [View Article][PubMed]
    [Google Scholar]
24. Seeger C., Sohn J.A. 2014; Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids 3:e216 [View Article][PubMed]
    [Google Scholar]
25. Tian Y., Chen W.L., Ou J.H. 2011; Effects of interferon-α/β on HBV replication determined by viral load. PLoS Pathog 7:e1002159 [View Article][PubMed]
    [Google Scholar]
26. Weber N.D., Stone D., Sedlak R.H., De Silva Feelixge H.S., Roychoudhury P., Schiffer J.T., Aubert M., Jerome K.R. 2014; AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One 9:e97579 [View Article][PubMed]
    [Google Scholar]
27. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., Trepo C., Marcellin P., Goodman Z., Delaney W.E. IV 2004; Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750–1758 [View Article][PubMed]
    [Google Scholar]
28. Wilson A.C., Patient R.K. 1991; Evaluation of extrachromosomal gene copy number of transiently transfected cell lines. Methods Mol Biol 7:397–404[PubMed]
    [Google Scholar]
29. Xie Y.H., Hong R., Liu W., Liu J., Zhai J.W. 2010; Development of novel therapeutics for chronic hepatitis B. Virol Sin 25:294–300 [View Article][PubMed]
    [Google Scholar]
30. Yuen K.S., Chan C.P., Wong N.H., Ho C.H., Ho T.H., Lei T., Deng W., Tsao S.W., Chen H., other authors. 2015; CRISPR/Cas9-mediated genome editing of Epstein–Barr virus in human cells. J Gen Virol 96:626–636 [CrossRef]
    [Google Scholar]
31. Zhen S., Hua L., Liu Y.H., Gao L.C., Fu J., Wan D.Y., Dong L.H., Song H.F., Gao X. 2015; Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther 22:404–412 [View Article][PubMed]
    [Google Scholar]